Digestion
Original Paper: Colorectal Cancer
K-ras and p53 Mutations in Colonic Lavage Fluid of Patients with Colorectal NeoplasiasHeinzlmann M. · Neynaber S. · Heldwein W. · Folwaczny C.Department of Gastroenterology, Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität, München, Germany
|
|
Digestion 2001;63:229–233
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: June 29, 2001
Issue release date: 2001
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4
ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)
For additional information: https://www.karger.com/DIG
Abstract
Background: The adenoma-carcinoma sequence has its molecular basis in several gene mutations of which K-ras and p53 are of paramount importance. The aims of this study were to evaluate whether these genetic alterations can be detected in colonic lavage fluid from patients with colorectal adenomas and carcinomas. Methods: In 45 patients with adenomas, 20 patients with colorectal carcinomas and 38 patients with non-neoplastic and noninflammatory diseases of the colon p53 and K-ras mutations were evaluated in colonic lavage fluid employing single-strand confirmation polymorphism analysis and dot-blot hybridization, respectively. Results: Mutations of the K-ras and the p53 gene were found in 15.6% (p = 0.065) of patients with adenomas, in 25.0 % (p = 0.016) of patients with carcinomas and in 2.6% in the control group. Conclusion: Genetic alterations in the colonic lavage fluid could be an additional diagnostic tool for the surveillance of patients with colorectal neoplasias.
© 2001 S. Karger AG, Basel
Related Articles:
References
-
Bresalier RS, Kim YS: Malignant neoplasms of the large intestine; in Feldman M, Scharschmidt BF, Sleisenger MH (eds): Gastrointestinal and Liver Disease. Philadelphia, Saunders, Philadelphia, 1993, vol 2, pp 1906–1942.
- Moertel CG, O’Fallon JR, Go VL, O’Conell MJ, Thynne GS: The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986;58:603–609.
- Boyle P, Zaridze DG, Smans M: Descriptive epidemiology of colorectal cancer. Int J Cancer 1985;36:9–15.
- Atkin WS, Morson BC, Cuzik J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658–662.
- Otchy DP, Ransohoff DF, Wolff BG, Weaver A, Ilstrup D, Carlson H, Rademacher D: Metachronous colon cancer in persons who have had a large adenomatous polyp. Am J Gastroenterol 1996;91:448–464.
- Van Stolck RU, Beck GJ, Baron JA, Haile R, Summers R: Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The polyp prevention study group. Gastroenterology 1998;115:13–18.
- Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C: A systematic review of the effects of screening for colorectal cancer using the fecal occult blood test, hemoccult. BMJ 1998;317:559–565.
- Rasmussen M, Kronborg C, Fenger C, Jorgenssen OD: Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol 1999;34:73–78.
- Anwar S, White J, Hall C, Farrell WE, Deakin M, Elder JB: Sporadic colorectal polyps: Management options and guidelines. Scand J Gastroenterol 1999;34:4–11.
- Muller AD, Sonnenberg A: Protection by endoscopy against death from colorectal cancer. A case control study among veterans. Arch Intern Med 1995;155:1741–1748.
- Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM: Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572–1575.
- Selby JV, Friedmann GD, Quesenberry CP, Weiss NS: A case-control study of screening sigmoidoscopy and mortality of colorectal cancer. N Engl J Med 1992;326:653–657.
- Bensen S, Mott LA, Dain B, Rothstein R, Baron J: The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps: Polyp prevention study group. Am J Gastroenterol 1999;94:194–199.
- Rex DK, Lehman GA, Ulbright TM, Smith JJ, Hawes RH: The yield of a second screening flexible sigmoidoscopy in average risk persons after one negative examination. Gastroenterology 1994;106:593–595.
- Sidransky D: Nucleic acid-based methods for the detection of colorectal cancer. Science 1997;278:1054–1058.
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM Bos JL: Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525–532.
- Fearon ER, Vogelstein B: A genetic model for colorectal carcinogenesis. Cell 1990;61:759–767.
- Cho KR, Vogelstein B: Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992;70:1727–1731.
- Toribara NW, Sleisenger MH: Screening for colorectal cancer. N Engl J Med 1995;332:861–867.
-
Hahn SA, Kern SE, Schmiegel WH: Molekularbiologische Veränderungen bei gastrointesti-nalen Tumoren. Diagnostische und therapeutische Perspektiven. Dtsch Ärzteblatt 1995;92:B157–B163.
- Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF, Quirke P: Prognostic value of p53 over-expression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57–64.
- Carson DA, Lois A: Cancer progression and p53. Lancet 1995;346:1009–1011.
- Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain A, Remvikos Y, Girodet J, Salmon RJ, Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42–48.
- Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260:85–88.
- Ookawa K, Sakamoto M, Hirohashi S, Yoshida Y, Sugimura T, Terada M, Yokota J: Concordant p53 and DCC alterations and allelic losses an chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer 1993;53:382–387.
- Sun XF, Carstensen JM, Stal O, Zhang H, Nilsson E, Sjodahl R, Nordenskjold B: Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch [A] 1993;423:443–448.
- Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of ras oncogene mutations in the stool of patients with resectable colorectal cancer. Science 1992;256:102–105.
- Smith-Ravin J, England J, Talbot IC, Bodmer W: Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995;36:81–86.
- Ulvik A, Aarskog NK, Ogreid D: Detection and identification of Ki-ras exon 1 mutations by minigel single-strand confirmation polymorphism. Anal Biochem 1995;232:137–138.
-
Tobi M, Luo FCh, Ronai Z: Detection of K-ras mutations in colonic effluent samples from patients without evidence of colorectal carcinoma. Reports J Nat Cancer Institute 1994;86:1007–1010.
- Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, Losi L, Perini M, Trande P, Merighi A, Lerose R, Manenti F: Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996;110:1346–1353.
- Nollau P, Moser C, Weinland G, Wagener C: Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996;66:332–336.
- Ratto C, Flamini G, Sofo L, Nucera P, Ippoliti M, Curigliano G, Ferretti G, Sgambato A, Merico M, Doglietto GB, Cittadini A, Crucitti F: Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum 1996;39:1238–1244.
-
Eguchi S, Kohara N, Komuta K, Kanematsu T: Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996;(suppl 77):1707–1710.
- Lang SM, Heinzlmann, M, Stratakis DF, Teschauer W, Loeschke K: Detection of Ki-ras mutations and differential hybridization and of p53 mutations by SSCP analysis in endoscopically obtained lavage solution from patients with long-standing ulcerative colitis. Am J Gastroenterol 1997;92:2166–2170.
- Lang SM, Stratakis DF, Heinzlmann M, Heldwein W, Wiebecke B, Loeschke K: Molecular screening of patients with long-standing extensive ulcerative colitis: Detection of p53 and Ki-ras mutations by single strand confirmation polymorphism analysis and differential hybridization in colonic lavage fluid. Gut 1999;44:822–825.
- Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun M, Mulcahy HE, Farthing MJ: K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997;112:1114–1120.
- Mayall F, Jacobson G, Wilkins R, Chang B: Mutations of p53 can be detected in the plasma of patients with large bowel carcinoma. J Clin Pathol 1998;51:611–613.
Article / Publication Details
First-Page Preview
Published online: June 29, 2001
Issue release date: 2001
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 4
ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)
For additional information: https://www.karger.com/DIG
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
